StockData

Annovis Bio vs CervoMed

ANVS and CRVO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ANVS and CRVO compare

Annovis Bio is the larger company, worth 1.4 times as much as CervoMed ($31.7M against $22.7M).

CervoMed scores higher on the StockData Score (5 against 4 for Annovis Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricANVSCRVO
Size and price
Market cap$31.7M$22.7M
Share price$0.743$1.50
Change, 1 year−68.2%−80.5%
Change, 5 years−97.1%−94.9%
Beta (5Y)3.473.41
Employees815
StockData Score
Total score45 (better)
Valuation score01 (better)
Growth score00
Performance score00
Health score44
Dividend score00
Valuation
P/S–68.5×
P/B–1.0×
Growth
Revenue growth (TTM)–−95.7%
Profitability
Operating margin–−9407%
Net margin–−9161%
Return on equity−704%−108% (better)
Financial health
Debt / equity–0.00
Altman Z-score−19.15−5.50 (better)
Piotroski F-score3 (better)1
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions25.5%11.6%
Held by insiders23.1%36.9%
Insider net buying, 12 months$6.8M (better)$3.0M
Short interest, % of float16.3%12.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.